April L. Kennedy,Bryson Rast,D. David Hennings,Fredrik P. Marmsater,George T. Topalov,James P. Rizzi,Mark C. Munson,Mark Laurence Boys,Martha E. Rodriguez,Matthew Medina,Michael Bradley,Qian Zhao,Robe
申请号：
BR112012017123
公开号：
BR112012017123A2
申请日:
2010.12.20
申请国别(地区):
BR
年份:
2017
代理人:
摘要：
n- (1h-indazol-4-yl) imidazo [1,2-a] pyridine-3-carboxamide compounds as cms inhibitors. compounds of formula (i): and pharmaceutically acceptable salts thereof, in which r ^ 1 ^, r ^ 2 ^, r ^ 3 ^, r ^ 4 ^ and r ^ 5 ^ have the meanings given in the descriptive report, are inhibitors of cfms and are useful in treating bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular disease, and pain.compostos de n-(1h-indazol-4-il)imidazo [1,2-a]piridina-3-carboxamida como inibidores de cfms. compostos de fórmula (i): e sais farmaceuticamente aceitáveis dos mesmos, nos quais r^1^,r^2^,r^3^,r^4^ e r^5^ têm os significados dados no relatório descritivo, são inibidores de cfms e são úteis no tratamento de doenças relacionadas a osso, câncer, distúrbios autoimunes, doenças inflamatórias, doenças cardiovasculares e dor.
